Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
1. Eli Lilly's obesity drugs may yield over $30 billion by 2035. 2. Analysts highlight muscle preservation as a selling point for treatments.
FAQ
Why Very Bullish?
The projected $30 billion in sales indicates strong growth potential for LLY, resembling historical increases seen in diabetes drugs. Similar outcomes were observed with weight-loss drugs like Saxenda and Ozempic, positively impacting their respective companies' stock prices.
How important is it?
The forecasted sales figure reflects increased market demand and could elevate LLY's stock trajectory. Eli Lilly's focus on this therapeutic area aligns with current health trends, indicating high investor interest.
Why Long Term?
Given the 2035 projections, LLY's strategic positioning in a growing market suggests sustained benefits. Historical patterns indicate that companies investing in obesity treatments have benefited significantly over similar time horizons.